UPDATE: Danaher Q2 Revenues Up 4 Percent, Beating Analyst Estimates | GenomeWeb

The story has been updated with comments from Danaher's second-quarter earnings conference call.

NEW YORK (GenomeWeb News) – Danaher today reported a 4 percent year-over-year increase in revenues for the second quarter, while Life Sciences and Diagnostics revenues rose nearly 6 percent.

For the three months ended June 28, the Washington, DC-based conglomerate pulled in total revenues of $4.74 billion, up from $4.55 billion, topping the consensus Wall Street estimate of $4.72 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.